期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

舒尼替尼治疗晚期危重低分化甲状腺癌一例 被引量：1

Case report： One patient with advanced and poorly differentiated thyroid carcinoma in crisis treated with sunitinib
原文传递
导出
摘要 低分化甲状腺癌比较少见，恶性程度高，易转移，病情进展快，治疗方法有限，预后差。本文就舒尼替尼治疗术后复发晚期危重低分化甲状腺癌患者获得部分缓解做一个案报道，为晚期危重低分化甲状腺癌分子靶向治疗提供参考。
作者 李金铎 姜镕 王斌 马春华 孙立伟 吕远
机构地区 天津市环湖医院肿瘤介入科、天津市脑血管与神经变性重点实验室
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2015年第3期285-287,共3页 Chinese Journal of Endocrinology and Metabolism
关键词 甲状腺癌 治疗方法 舒尼替尼 低分化 危重 晚期 分子靶向治疗 恶性程度
分类号 R736.1 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma[ J]. Lancet Oncol, 2007,8 ( 2 ) : 148-156.
  • 2关海霞,叶蕾.靶向药物酪氨酸激酶抑制剂治疗甲状腺癌的临床研究进展[J].中华内分泌代谢杂志,2012,28(10):798-801. 被引量：3
  • 3Marotta V, Ramundo V, Camera L, et al. Sorafenib in advanced iodine- refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET [ J ]. Clin Endocrinol (Oxf) , 2013,78 ( 5 ) : 760-767.
  • 4National Cancer Institute. Surveillance Epidemiology and End Results [ online ]. http://seer, cancer, gov/statfacts/html/thyro, html # incidence-mortality(2013).
  • 5Nixon I J, Shaha AR, Tuttle MR. Targeted therapy in thyroid cancer [ J ]. Curr Opin Otolaryngol Head Neck Surg, 2013,21 ( 2 ) : 130-134.
  • 6Cohen EE, Needles BM, Cullen K J, et al. Phase 2 study of sunitinib in refractory thyroid cancer [ J ]. J Clin Oncol ( 2008 ASCO Meeting Proceedings, Post-Meeting Edition) , 2008,26 ( 15 S) :6025.
  • 7Cart LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation[J]. Clin Cancer Res, 2010,16(21 ) :5260-5268.
  • 8Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine- refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial [ J ]. Lancet, 2014,384 (9940) :319-328.
  • 9Marotta V, Di Somma C, Rubino M, et al. Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib [ J ]. Endocrine, 2014, PMID: 25305056.
  • 10Dadu R, Devine C, Hemandez M, et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib [ J ]. J Clin Endocrinol Metab, 2014,99 ( 6 ) : 2086 -2094.

二级参考文献25

  • 1Vieira JM, Santos SC, Espadinha C, et al. Expression of vascular endothelial growth factor (VEGF) and its receptors in thyroid carcinomas of follicular origin: a potential autocrine loop. Eur J Endocrinol, 2005,153:701-709.
  • 2Mitsiades CS, Kotoula V, Poulaki V, et al. Epidermal growth factor receptor as a therapeutic target in human thyroid carcinonm: nmtational and functional analysis. J Clin Endocrinol Metab, 2006,91:3662- 3666.
  • 3Croyle M, Akeno N, KnaufJA, et al. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res, 2008,68:4183-4191.
  • 4Xing M. Genetic-targeted therapy of thyroid cancer: a real promise. Thyroid, 2009,19:805-809.
  • 5Ye L, Santarpia L, Gagel RF. The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors. Endocr Rev, 2010,31 : 578 -599.
  • 6Carter WB, Tourtelot JB, Savell JG, et al. New treatments and shifting paradigms in differentiated thyroid cancer management. Cancer Control, 2011, 18:96-103.
  • 7Sherman SI, Wirth LJ, Droz JP, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med, 2008,359:31 - 42.
  • 8Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histological subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol, 2008,26:4708-4713.
  • 9Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol, 2008,26 : 4714- 4719.
  • 10Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Ciin Oncol, 2009,27:1675-1684.

共引文献2

同被引文献7

引证文献1

二级引证文献5

中华内分泌代谢杂志
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部